Previous close | 0.5000 |
Open | 0.5500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 6.00 |
Expiry date | 2024-09-20 |
Day's range | 0.5000 - 0.5500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Recursion Pharmaceuticals Inc is a biotechnology firm that utilizes an AI-driven platform to accelerate drug discovery and development processes. Over the past year, Blake Borgeson has engaged in multiple transactions involving the company's stock, selling a total of 350,970 shares and making no purchases. Shares of Recursion Pharmaceuticals Inc were priced at $9.51 on the day of the transaction.
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a price to the public of $6.50 per share. All of the shares are to be sold by Recursion. In addition, Recursion has granted the underwriters a 30-day option to purchase up to an add
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that it intends to offer and sell $200.0 million of shares of its Class A common stock in an underwritten public offering. All of the shares of Class A common stock are being offered by Recursion. In addition, Recursion intends to grant to the underwriters a 30-day option to purch